MHRA Investigates UK Peptide Clinics Over Health Claims

The medicines regulator in the UK, the Medicines and Healthcare products Regulatory Agency (MHRA), is investigating whether clinics are breaking the law by making claims about the benefits of unregulated, experimental peptide therapies. This scrutiny comes amid a boom in interest for these injectable substances, promoted for anti-ageing, injury recovery, and more. However, there is little scientific evidence to support such health and wellness claims in humans, with most studies limited to animals or cells.

The Rise of Experimental Peptide Therapies in the UK

Peptides are short chains of amino acids, some of which occur naturally in the body, like the hormone insulin that regulates blood sugar levels. In recent years, there's been a surge in using peptides for therapeutic purposes, including weight loss, anti-ageing, and injury recovery. While approved prescription medications like semaglutide (in Wegovy) and tirzepatide (in Mounjaro) are synthetic peptides mimicking natural hormones and have undergone strict regulatory review, many others remain experimental and unregulated.

Interest has exploded, fueled by sellers, influencers, and even some medics. Clinics offer these via injection, but the MHRA states they cannot make medicinal claims. "If clinics offering peptide injections make medicinal claims for those treatments, the products will be considered medicines and subject to regulation under the Human Medicines Regulations 2012," an MHRA spokesperson said. "The MHRA will take action against clinics which are identified as breaching the legal requirements."

A Guardian Investigation Uncovers Problematic Claims

A Guardian investigation revealed several UK clinics promoting unregulated peptides with bold health claims on their websites, despite top Google search rankings for "peptide clinics in the UK." One leading site claimed Cortexin is "used for neuroprotection and cognitive enhancement," BPC-157 "aids in tissue repair and recovery from injuries," and Thymosin Alpha "boosts immune function."

The MHRA confirmed these constitute medicinal claims, which are not permitted. After the Guardian's inquiry, the clinic removed the claims. Another top clinic acknowledged limited human evidence and labeled peptides "research only," yet listed seven named peptides with "results duration" and prices: £350 monthly for one peptide or £450 for two, available in vials with syringes or pre-loaded pens for an extra fee.

Insights from a Clinic Consultation

During a free consultation with a reporter, the clinician noted most peptide research is pre-clinical, with no large randomized multi-center trials on long-term effects. They recommended cycling: four to eight weeks off after two to three months of use to mitigate risks.

For exercise recovery and fatigue, two peptides were suggested. First, BPC-157: "It helps in repair and recovery of cells. So if somebody comes to us saying I want to get fitter, lift heavier, get bigger muscle, I will still recommend BPC-157, even though it doesn't directly affect any of those things. It's because it helps your recovery after those workouts." The clinician explained it provides more blood flow and nutrients to tissues, promoting quicker recovery. However, BPC-157 is not advised for smokers or those with a family history of cancer, due to concerns it could increase blood supply to such tissues.

Second, MOTS-C: "MOTS-C is something that helps provide more stress resilience and better health to your mitochondria to be able to produce more energy cells ... so the direct net effect for you would be reduced insulin resistance, better energy production in the form of [the energy molecule] ATP, and the net result of that is basically reduce visceral fat."

The MHRA is assessing if these verbal claims qualify as medicinal. The clinic responded: "We have clearly explained that the peptides discussed are not licensed medicines, and that the current evidence base is largely pre-clinical, with an absence of large-scale randomised controlled trials assessing long-term outcomes." They emphasize shared decision-making with balanced info on mechanisms, benefits, and uncertainties.

MHRA's Regulatory Stance on Peptides

The MHRA defines a medicinal product as any substance presented for preventing or treating disease (including injury or ailment), or for restoring/correcting physiological functions via pharmacological, immunological, or metabolic action. Lynda Scammell, head of borderline products at the MHRA, explained: "Peptide products may be sold as cosmetics, supplements and medicines, and depending on their intended purpose, they fall under different regulatory frameworks."

Decisions are case-by-case, considering effects, usage, evidence, and precedents. "We disregard claims that products are for 'research purposes' if it is clear that such claims are being used as an attempt to avoid medicines regulations. If there is evidence within the promotional material that the products are in fact unauthorised medicines intended for human use, we will take appropriate regulatory action."

Clinics note unregulated access via online networks lacks oversight, quality, or safety screening.

How Experimental Peptides Differ from Approved GLP-1 Medications

Unlike experimental peptides, GLP-1 agonists like semaglutide and tirzepatide in Wegovy and Mounjaro have rigorous clinical trial data supporting safety and efficacy for weight management and metabolic health. These mimic gut hormones to regulate appetite and blood sugar. Experimental peptides lack such validation, relying on animal/cell data, raising risks of unknown long-term effects.

Patient Guidance: What to Consider Before Peptide Therapy

Given the regulatory concerns and evidence gaps, patients should approach peptide clinics cautiously. Discuss any interest with a qualified healthcare provider familiar with your medical history. Key risks include lack of long-term data; for BPC-157, avoid if smoking or with cancer family history. Cycle use as advised to potentially reduce risks.

Track symptoms, side effects, or injection schedules with apps like Shotlee to monitor your response safely. Prioritize licensed therapies for proven needs like metabolic health.

Key Takeaways

• MHRA is investigating UK clinics for medicinal claims on peptides like BPC-157, Cortexin, and MOTS-C.
• Claims include tissue repair, cognitive enhancement, immune boost, and fat reduction, but human evidence is limited.
• Clinics stress pre-clinical status yet promote with prices and consultations.
• Approved peptides like semaglutide contrast with strict testing; experimentals risk regulatory action.
• Patients: Consult doctors, heed warnings, track usage carefully.

Conclusion

This MHRA investigation highlights the tension between booming peptide interest and regulatory safeguards. While clinics offer experimental options amid unmet needs, unauthorized claims could lead to enforcement. Patients seeking metabolic health or recovery benefits should weigh evidence, prioritize approved options, and stay informed on UK regulations for safe choices.